BioSenic and its subsidiary Medsenic have announced the filing of a continuation patent application with the United States Patent & Trademark Office, seeking to extend the protection for the use of arsenic trioxide (ATO) in the prevention and treatment of sepsis syndrome.

The application, numbered US 18/763,376, aims to cover the use of Medsenic’s ATO platform to prevent or eradicate the cytokine storm associated with systemic infection.

The US patent application could lead to further divisional filings, especially at the European Patent Office.

The patent extension covers two primary areas: immune and autoimmune-related diseases, including chronic graft-versus-host disease, systemic sclerosis and systemic lupus erythematosus, and oncology, where ATO has shown promising results in acute promyelocytic leukaemia patients.

The expanding patent family underpins Medsenic/BioSenic’s international clinical trials for pathologies lacking effective treatments.

The company aims for market access approvals for a range of formulations, refining the original properties of arsenic salts, alone or in combination.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BioSenic anticipates the availability of intravenous and oral formulations combining arsenic and copper, positioning the company to leverage preclinical achievements.

Medsenic/BioSenic plans to continue the clinical development with formulations incorporating arsenic and new active ingredients such as metal ions, to enhance product efficacy and reduce side effects.

BioSenic chairman and CEO François Rieger stated: “The current effort to improve the field of indications and a broader intellectual property for the use of original formulations and composition of matter related to the extraordinary properties of arsenic salts should give a dramatic impetus to the clinical and commercial development of the company.

“Arsenic salts are now found to exhibit critical and very original biological properties that should help provide new ways to treat diseases of the immune system and, further, cancer conditions with no effective medical treatment.

“It is of great interest that pharmacological formulations containing arsenic salts are often found to redirect organisms towards normal functioning of various cells and organs and restore homeostasis.”